PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-2.79%
Negative net income growth while CRVO stands at 17.10%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-4.72%
Negative yoy D&A while CRVO is 8.23%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-4.68%
Both cut yoy SBC, with CRVO at -23.71%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
284.52%
Slight usage while CRVO is negative at -214.77%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
299.08%
A yoy AP increase while CRVO is negative at -154.97%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-348.88%
Both reduce yoy usage, with CRVO at -284.76%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
208.62%
Some yoy increase while CRVO is negative at -33.87%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
35.18%
Some CFO growth while CRVO is negative at -57.98%. John Neff would note a short-term liquidity lead over the competitor.
82.00%
CapEx growth of 82.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
82.00%
We expand invests by 82.00% while CRVO is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.